‘Platinum’ male enhancement supplements recalled because they contain undeclared drugs for erectile dysfunction: FDA

by Editorial Team

“Platinum” male enhancement supplements have been recalled because they contain undeclared drugs used for erectile dysfunction, the FDA announced Tuesday.

The supplements, named “Bull Platinum 30000,” “Stallion Platinum 30000,” “Rhino 7 Platinum 30000” and “Panther Platinum 30000″ and manufactured by Motto International Corp., were found to contain the undeclared drug tadalafil, which is used to treat erectile dysfunction.

Taldalafil, sold under the brand names Adcirca and Cialis, according to the Mayo Clinic, is a prescription-only drug.

People who take prescription drugs containing nitrates may be at risk if they consume a supplement with undeclared taldalafil, as it may cause low blood pressure that could drop to “life threatening” levels, the FDA warned.

Motto International Corp. issued a voluntary recall of the drugs, the FDA announced Tuesday.

“Motto International Corp. is notifying its customers by email and is arranging for replacement of recalled products, at the request of the customer. Consumers who purchased the product in October, 2019 should stop consuming it and return any unused product to Motto International Corp., Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product,” the FDA said in a statement.

The affected lots were sold in 2, 4 or 10-pack cards, and were distributed to two local Dallas convenience stores, the FDA said. No reports of adverse incidents have been reported.

This is not the first time male enhancement drugs have been recalled due to undeclared drugs for erectile dysfunction.

In July, “Big Penis” male sexual stimulants were recalled because they contained slidenafil, which is found in the prescription drug Viagra.

READ FROM SOURCE: https://www.nydailynews.com/news/national/ny-platinum-enhancement-supplements-recalled-contain-dysfunction-20191218-kogscdb4rbesfhxragpg35afmq-story.html

Related Posts

Leave a Comment